Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence

NCT03443856 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

197

Enrollment

NETWORK

Sponsor class

Conditions

Gastric and Esophagogastric Junction Adenocarcinoma

Interventions

DRUG: Nivolumab and Ipilimumab
OTHER: chemotherapy

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC